- Dyne Therapeutics (DYN) announced on Tuesday that it has commenced an underwritten public offering of $300M of its common stock.
- The underwriters have a 30-day option to purchase up to an additional $45M of common stock, bringing the total potential offering size to $345M.
- The offering is subject to market conditions, and the company said there is no assurance on the timing, completion, or final size of the offering.
- The DYN stock traded ~14% lower at ~$20.50 in the after-hours trading.
More on Dyne Therapeutics
- Dyne Therapeutics: A Buy, With Caveats, On DMD Progress
- Dyne Therapeutics: 'Strong Buy' Due To Upcoming Z-Rostudirsen BLA Submission
- Dyne gains FDA acceptance of z-rostudirsen BLA for Duchenne muscular dystrophy
- Dyne Therapeutics expands debt facility with Hercules Capital to $400M
- Seeking Alpha’s Quant Rating on Dyne Therapeutics